ReviewWorld journal of gastroenterology2014
Cytomegalovirus infection in liver transplant recipients: updates on clinical management.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 58 citations in OpenAlex.
- Article
- Healthcare disparity and its associations with cytomegalovirus disease in pediatric liver transplant recipients in South Africa.Transplant infectious disease : an official journal of the Transplantation Society · 2022Article
- Cytomegalovirus infection in liver-transplanted children.World journal of hepatology · 2022Review
- Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation.Diagnostics (Basel, Switzerland) · 2021Article
- Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients.Vaccines · 2021Article
- Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers.Journal of clinical medicine · 2020Article
- Donor-derived Viral Infections in Liver Transplantation.Transplantation · 2018Review
- Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure.The Journal of international medical research · 2018Article
- Single-cycle adenovirus vectors in the current vaccine landscape.Expert review of vaccines · 2018Review
- Cytomegalovirus in the Pediatric Transplant Recipient: Where Are We Now?Transplantation · 2017Article
- Effectiveness of Preemptive Therapy for Cytomegalovirus Disease in Pediatric Liver Transplantation.Transplantation · 2017Article
- Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.Nucleic acids research · 2016Review
- Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes.Seminars in respiratory and critical care medicine · 2016Review
- Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention.Current infectious disease reports · 2016Article
- Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.PloS one · 2015Article
- Earlier and higher rates of cytomegalovirus infection in pediatric liver transplant recipients as compared to adults: An observational study.Journal of laboratory physiciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) infection is a common complication after liver transplantation, and it is associated with multiple direct and indirect effects. Management of CMV infection and disease has evolved over the years, and clinical guidelines have been recently updated. Universal antiviral prophylaxis and a pre-emptive treatment strategy are options for prevention. A currently-recruiting randomized clinical trial is comparing the efficacy and safety of the two prevention strategies in the highest risk D+R- liver recipients. Drug-resistant CMV infection remains uncommon but is now increasing in incidence. This highlights the currently limited therapeutic options, and the need for novel drug discoveries. Immunotherapy and antiviral drugs with novel mechanisms of action are being investigated, including letermovir (AIC246) and brincidofovir (CMX001). This article reviews the current state of CMV management after liver transplantation, including the updated practice guidelines, and summarizes the data on investigational drugs and vaccines in clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.